Renaissance Technologies LLC Cuts Position in Jazz Pharmaceuticals PLC $JAZZ

Renaissance Technologies LLC lessened its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 819,374 shares of the specialty pharmaceutical company’s stock after selling 17,400 shares during the quarter. Renaissance Technologies LLC’s holdings in Jazz Pharmaceuticals were worth $154,903,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Cardinal Capital Management lifted its holdings in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after buying an additional 66 shares in the last quarter. Bessemer Group Inc. grew its stake in Jazz Pharmaceuticals by 0.3% during the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after purchasing an additional 73 shares in the last quarter. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 12.6% during the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 81 shares in the last quarter. Pinnacle Associates Ltd. increased its stake in shares of Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after buying an additional 83 shares during the period. Finally, Fifth Third Wealth Advisors LLC grew its holdings in Jazz Pharmaceuticals by 4.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after acquiring an additional 85 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 0.4%

JAZZ opened at $253.87 on Friday. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $256.75. The business has a 50 day moving average price of $237.37 and a two-hundred day moving average price of $203.24. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company has a market cap of $15.95 billion, a PE ratio of -12,687.16, a P/E/G ratio of 0.22 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion for the quarter. As a group, research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on JAZZ shares. Barclays raised their price target on Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Needham & Company LLC upped their price objective on shares of Jazz Pharmaceuticals from $255.00 to $282.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Truist Financial dropped their price objective on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Bank of America lifted their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $259.06.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the sale, the director owned 366,682 shares of the company’s stock, valued at approximately $88,176,020.54. The trade was a 1.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 13,098 shares of company stock worth $3,131,906 in the last three months. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.